Abstract
Adriamycin (ADM) is one of the anticancer agents occasionally used in Japan. There are some reasons why the agent is not so frequently used as in Europe and USA. The first reason is the frequent use of mitomycin C. Because of its potent anticancer effect and broad anticancer spectrum, mitomycin C is one of the most widely used anticancer agents in Japan. The second reason is the intense side reactions of ADM. Especially, the high incidence of severe alopecia restricts the wide use of this agent. Table 1 shows the side reactions of ADM that have developed in 810 cases recently treated with single administration of ADM in Japan. Side effects on the digestive system, alopecia and bone marrow toxicity are considerably frequent, and cardiotoxicities such as tachycardia, ECG change, arrhythmia are also frequent.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Furue, H., Komita, T. (1978). Clinical Aspects of Adriamycin in Japan. In: Carter, S.K., Umezawa, H., Douros, J., Sakurai, Y. (eds) Antitumor Antibiotics. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 63. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81219-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-81219-4_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81221-7
Online ISBN: 978-3-642-81219-4
eBook Packages: Springer Book Archive